Nemluvio (nemolizumab-ilto) / Roche, Maruho, Galderma - LARVOL DELTA

Continuous response with nemolizumab - Efficacy and safety up to 104 weeks in patients with moderate-to-severe atopic dermatitis with partial and non-response in skin at 16 weeks: Post hoc analyses from the ARCADIA LTE trial (AAD 2026) - P3 | "Although some patients with moderate-to-severe AD did not achieve the defined skin response criteria with nemolizumab at W16, continuing treatment in combination with topical therapies led to a meaningful and sustained clinical improvement over the longer term."

Clinical • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus

Long-term efficacy and safety of nemolizumab in adolescents with moderate-to-severe atopic dermatitis: Post hoc analyses from ARCADIA LTE 2-year cut-off (AAD 2026) - P3 | "Overall, nemolizumab was well-tolerated through W104, with sustained and increased improvements in skin lesions, itch, sleep, and quality of life."

Clinical • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Long-term (up to 104 weeks) maintenance of itch and skin responses with nemolizumab treatment in patients with moderate-to-severe atopic dermatitis – Post hoc analyses from the ARCADIA long-term extension trial (AAD 2026) - P3 | "Long-term (until W104) nemolizumab treatment maintained clinical improvements in itch and skin lesions in moderate-to-severe AD."

Clinical • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Clinical Response of a Patient with Steroid-Refractory Lichen Planus to Nemolizumab Therapy: A Case Report (AAD 2026) - "The patient’s rash and severe pruritus were refractory to oral antihistamines, several topical corticosteroids, and oral prednisone. Further studies are needed to characterize the mechanism of pruritus in LP and the role of IL-31 in pathogenesis. Prospective trials evaluating nemolizumab’s safety and efficacy in LP are also warranted."

Case report • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Lichen Planus • Prurigo Nodularis • Pruritus

Efficacy and Safety of Nemolizumab in Patients with Prurigo Nodularis: A Systematic Review and Meta-Analysis (AAD 2026) - "This review confirms Nemolizumab as an effective, well-tolerated treatment for Prurigo Nodularis, Offering prompt improvement in pruritus, skin lesions, and sleep disturbances. With a favorable safety profile, that marks a major advancement in managing this challenging, underserved condition."

Retrospective data • Review • CNS Disorders • Dermatitis • Immunology • Infectious Disease • Prurigo Nodularis • Pruritus • Sleep Disorder

Reassessing Long-Term Safety and Efficacy of Topical and Systemic Therapies in Atopic Dermatitis: An Updated Comparative Review (AAD 2026) - "Topical agents such as high-potency corticosteroids, phosphodiesterase-4 inhibitors, tacrolimus, ruxolitinib, mucopolysaccharide polysulfate cream, and tapinarof cream were found to be effective in improving skin lesions and pruritus in mild-to-moderate AD...Biologics such as dupilumab, lebrikizumab, tralokinumab, and nemolizumab, as well as JAK inhibitors including abrocitinib and upadacitinib, consistently improved EASI scores and overall disease severity. Despite these advances, the limited number of robust comparative studies and standardized criteria for transitioning between treatment classes continues to limit evidence-based decision-making. In the absence of large-scale clinical trials, network meta-analyses and expert consensus panels could be utilized to clarify long-term safety, refine sequencing strategies, and enhance the generalizability of treatment recommendations."

Clinical • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus

Early persistence of abrocitinib use in biologic-naive and biologic-exposed adult patients with moderate to severe atopic dermatitis: a real world study (AAD 2026) - "Characteristics were summarized for biologic-exposed (≥1 fill of Dupilumab, Lebrikizumab, Nemolizumab, or Tralokinumab) and biologic-naïve patients prior to abrocitinib initiation. Both biologic-naïve and biologic-exposed patients demonstrated early persistence of abrocitinib in both adolescents and adults, supporting its tolerability and perceived efficacy both as initial and subsequent advanced treatment for M2S AD."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Evolving Real-World Treatment Patterns and Unmet Needs in Atopic Dermatitis in the United States: Insights from a 2025 Patient Chart Audit and Market Landscaping Study (AAD 2026) - "Lebrikizumab and nemolizumab also sourced patients from tralokinumab, while upadacitinib remained constant at 10% of first-line new start patients. Although dupilumab leads first-line use, rapid uptake of lebrikizumab, nemolizumab, and upadacitinib reflects an evolving landscape. Continued under-treatment, inadequate itch control, and limited sustained response highlight opportunities for innovation to optimize outcomes in AD."

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody (AAD 2026) - "It potently inhibits IL31 activity in IL31R-STAT and HaCaT assays, outperforming Nemolizumab and NM26-2198 analogues. Meanwhile, HXN-1022 exhibits robust in vitro activity for OX40L in the OX40-NFκB reporter assay, OX40L-induced PBMC activation, and Th2 differentiation experiments, with potency comparable to Amlitelimab... HXN-1022 is a first-in-class bsAb that simultaneously targets IL-31 and OX40L, two key drivers of inflammation and pruritus in skin disease. These findings support HXN-1022 as a promising therapeutic candidate for AD and other autoimmune skin disorders. HXN-1022 is currently under IND-enabling studies."

Bispecific • Preclinical • Atopic Dermatitis • Dermatitis • Graft versus Host Disease • Immunology • Inflammation • Pruritus • IL1R1 • TNFSF4

Pharmacokinetics, safety, and efficacy of nemolizumab in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis (AAD 2026) - No abstract available

Clinical • Late-breaking abstract • PK/PD data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparative Efficacy of Targeted Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: an updated network meta-analysis (AAD 2026) - "Objective: To compare the relative efficacy of targeted systemic therapies (Dupilumab, Stapokibart, Tralokinumab, Lebrikizumab, Nemolizumab, Upadacitinib, Abrocitinib, Baricitinib, Ivarmacitinib) for moderate-to-severe AD without topical corticosteroids through network meta-analysis... Among targeted therapies for moderate-to-severe AD without concomitant topical TCS for 12 or 16 weeks, upadacitinib 30 mg demonstrated the most efficacious in this NMA."

Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Updating the American Academy of Dermatology Clinical Practice Guidelines for Systemic Treatment of Moderate to Severe Atopic Dermatitis in Adults (AAD 2026) - "Results The updated guideline addresses two clinical questions across seven approved systemic agents, including abrocitinib, baricitinib, dupilumab, lebrikizumab, nemolizumab, tralokinumab, and upadacitinib. . Conclusions This updated guideline provides clinicians with seven evidence-based recommendations to optimize systemic treatment selection for adults with moderate to severe AD, reflecting the current therapeutic landscape and supporting shared decision-making."

Clinical • Clinical guideline • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Medicaid Coverage as a Barrier to Biologic Access for Atopic Dermatitis: A Cross-Sectional Analysis of State Level Variability (AAD 2026) - "This study examines state-sponsored Medicaid preferred drug lists to assess coverage of the six FDA-approved biologics for AD: four injectables (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and two oral agents (upadacitinib, abrocitinib). While no significant association was observed between regional Medicaid enrollment and preferred drug status, findings highlight substantial variation in coverage across states, which may limit treatment options for patients depending on where they live. Future efforts should evaluate strategies, such as standardizing formulary criteria, to expand access to a broader range of Medicaid-covered biologics and assess the impact of these strategies on patient outcomes."

Medicaid • Reimbursement • US reimbursement • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

U090 Practical Considerations for Systemic Treatment of Atopic Dermatitis in Adults (AAD 2026) - "Conventional immunomodulators (methotrexate, cyclosporine), biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab), and JAK inhibitors (abrocitinib, upadacitinib) are available, with more on the way. 3. Differentiate the advantages and disadvantages of available systemic treatment options for atopic dermatitis in special populations of adults, including older adults and adults with comorbidities."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

AAD 2026: Galderma showcases latest evidence supporting its full-spectrum, science-driven solutions for diverse skin needs (Galderma Press Release) - "...Galderma will present data on the efficacy and safety of Nemluvio...This includes a late-breaking presentation assessing the pharmacokinetics, safety and efficacy of nemolizumab in pediatric patients (aged 2 to 11 years)...Additionally, an oral presentation of post hoc data from the ARCADIA long-term extension trial...will look at the long-term maintenance of itch and skin responses with Nemluvio up to 104 weeks...Two other posters will display data on Nemluvio’s long-term efficacy and safety up to two years in adolescents, and in patients with partial and minimal skin response at 16 weeks...Our product theater on Sunday...will deliver into the critical role of neuroimmune interactions in atopic dermatitis and prurigo nodularis, focusing on how targeted IL-31 treatment can improve patient outcomes."

Clinical data • Atopic Dermatitis • Immunology • Prurigo Nodularis

Galderma…announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year (Businesswire) - "Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting....Investigator’s Global Assessment of skin lesion improvement to clear (0) or almost clear (1) skin was observed as early as Week 4, with 41-47% of patients achieving it by Week 16. A 75% improvement in the Eczema Area and Severity Index score was observed as early as Week 4, with 69-73% of patients achieving it by Week 16. Itch relief - defined as a score of ≥4 on the Peak Pruritus Numerical Rating Scale (PP-NRS) - was observed as early as Week 1, with 72% of children aged 2 to 6 and 59% of children aged 7 to 11 achieving it at Week 1."

Late-breaking abstract • P2 data • Atopic Dermatitis

Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab. (PubMed, JID Innov) - "In conclusion, proteins and pathways involved in the systemic immune response modulated by nemolizumab were identified, potentially reflecting its therapeutic effects. The M525101-05 study (jRCT2080225290) was registered on July 22, 2020, and the MIT-502 study (jRCT1030230474) was registered on November 22, 2023."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

FDA-approved biologics for moderate-to-severe atopic dermatitis: A comparative review and the role of comorbidities for treatment selection (AAD 2026) - "Objectives: To compare FDA-approved biologics for AD - dupilumab, tralokinumab, lebrikizumab, and nemolizumab - focusing on how comorbidities influence treatment selection and outcomes. Targeted biologics have transformed moderate-to-severe AD management, offering more effective and tolerable alternatives to traditional systemic therapies. Distinct mechanisms, dosing regimens, and safety profiles enable individualized treatments based on disease severity. Comorbidity-driven biologic selection optimizes outcomes while minimizing risks, emphasizing the importance of precision medicine in AD management."

Review • Asthma • Atopic Dermatitis • Cardiovascular • Conjunctivitis • Dermatitis • Dermatology • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Respiratory Diseases • IL13 • IL4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

IL-31 Blockade Elevates TARC by Lifting LAMP3+ CD1c+ Mature Dendritic Cells from CGRP-CALCRL Neuroimmune Suppression in Atopic Dermatitis. (PubMed, J Allergy Clin Immunol) - "Findings support an IL-31-dependent CGRP-CALCRL neuroimmune brake that restrains DC maturation and TARC. IL-31RA blockade disinhibits this circuit, linking antipruritic therapy to DC-driven chemokine programs and offering a rationale for stronger TARC responses in patients than in the MC903 model. Monitoring TARC and neuroimmune context may aid management of nemolizumab-treated patients with AD."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • CALCRL • CD123 • CD1C • CD63 • CDK1 • IL31RA • LAMP3 • OSMR

Drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

RE-UNITE PN: Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults (clinicaltrials.gov) - P=N/A | N=600 | Recruiting | Sponsor: Galderma R&D | Not yet recruiting ➔ Recruiting

Enrollment open • Real-world evidence • Immunology • Prurigo Nodularis

Decision-Making Factors for Systemic Therapies in Atopic Dermatitis: A Clinical Review. (PubMed, Dermatitis) - "Dupilumab, tralokinumab, lebrikizumab, and nemolizumab are now FDA-approved biologics with demonstrated efficacy and favorable long-term safety, while oral Janus kinase inhibitors (JAKis) such as abrocitinib, upadacitinib, and baricitinib often provide rapid disease control but carry black-box warnings. Future directions emphasize head-to-head comparative studies, biomarker development for precision treatment, and equitable access to advanced therapies. This narrative review synthesizes current evidence on biologics and JAKis in AD, outlining efficacy, safety, and practical decision-making factors to guide dermatologists in aligning therapies with both clinical context and patient priorities."

Journal • Review • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Immunology • Infectious Disease • Oncology

AI-Guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody (AAAAI 2026) - "It effectively inhibits IL31 biological activity in the IL31R-STAT reporter assay and HaCaT cell activation, with superior efficacy to the benchmarks, Nemolizumab and NM26-2198 analogs. For the OX40L arm, HXN-1022 significantly blocks OX40L-induced downstream signaling and PBMC activation, with potency comparable to Amlitelimab...The bsAb represents a highly promising therapeutic option for patients with autoimmune skin disorders. HXN-1022 is currently under IND-enabling studies."

Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Graft versus Host Disease • Immunology • Inflammation • Pruritus • IL1R1 • TNFSF4

Comparison chart: Interleukin (IL) antagonists and oral JAK inhibitors for moderate to severe atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology